Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Price Target at $405.33

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-six research firms that are presently covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and twenty-two have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $405.3333.

A number of equities analysts recently commented on ALNY shares. Wall Street Zen upgraded Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Scotiabank lifted their price objective on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a “sector outperform” rating in a research report on Friday, August 1st. Citigroup lifted their price objective on Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the stock a “buy” rating in a research report on Friday, July 11th. HC Wainwright lifted their price objective on Alnylam Pharmaceuticals from $500.00 to $570.00 and gave the stock a “buy” rating in a research report on Thursday, August 7th. Finally, Oppenheimer upgraded Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 price objective on the stock in a research report on Monday, August 4th.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 1,455 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total value of $666,986.55. Following the sale, the executive vice president owned 20,221 shares in the company, valued at $9,269,508.61. The trade was a 6.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 31,640 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, May 30th. The shares were sold at an average price of $304.39, for a total value of $9,630,899.60. Following the completion of the sale, the chief executive officer owned 48,948 shares in the company, valued at $14,899,281.72. This represents a 39.26% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 108,531 shares of company stock valued at $41,087,238 in the last 90 days. 1.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Norges Bank acquired a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at $662,837,000. T. Rowe Price Investment Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 39.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company’s stock valued at $1,031,705,000 after buying an additional 1,245,195 shares in the last quarter. Holocene Advisors LP acquired a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at $194,616,000. Orbis Allan Gray Ltd grew its stake in shares of Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after buying an additional 486,489 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Alnylam Pharmaceuticals by 2.5% in the first quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock valued at $3,525,544,000 after buying an additional 323,206 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $458.31 on Monday. The company has a market cap of $60.08 billion, a PE ratio of -185.55 and a beta of 0.25. The stock’s 50 day simple moving average is $354.46 and its 200-day simple moving average is $294.11. Alnylam Pharmaceuticals has a 1-year low of $205.87 and a 1-year high of $466.31. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business had revenue of $773,689 billion for the quarter, compared to the consensus estimate of $633.54 million. During the same quarter last year, the business posted ($0.13) earnings per share. The business’s quarterly revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.